{"nctId":"NCT01106651","briefTitle":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2010-06"},"conditions":["Diabetes Mellitus, Type 2"],"count":716,"armGroups":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin 100 mg","Drug: Antihyperglycemic agent(s)"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin 300 mg","Drug: Antihyperglycemic agent(s)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Antihyperglycemic agent(s)","Drug: Placebo"]}],"interventions":[{"name":"Canagliflozin 100 mg","otherNames":[]},{"name":"Canagliflozin 300 mg","otherNames":[]},{"name":"Antihyperglycemic agent(s)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM and may be currently treated with a stable regimen of antihyperglycemic agent(s)\n* Patients in the study must have a HbA1c between \\>=7 and \\<=10.0%\n* Patients must have a fasting plasma glucose (FPG) \\<270 mg/dL (15 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.063"},{"groupId":"OG001","value":"-0.60","spread":"0.063"},{"groupId":"OG002","value":"-0.73","spread":"0.064"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"47.7","spread":null},{"groupId":"OG002","value":"58.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":"2.875"},{"groupId":"OG001","value":"-18.1","spread":"2.860"},{"groupId":"OG002","value":"-20.3","spread":"2.920"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.3"},{"groupId":"OG001","value":"-2.4","spread":"0.3"},{"groupId":"OG002","value":"-3.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition","description":"The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.336"},{"groupId":"OG001","value":"-1.87","spread":"0.332"},{"groupId":"OG002","value":"-2.38","spread":"0.323"}]}]}]},{"type":"SECONDARY","title":"Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition","description":"Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.270"},{"groupId":"OG001","value":"-1.03","spread":"0.268"},{"groupId":"OG002","value":"-1.18","spread":"0.261"}]}]}]},{"type":"SECONDARY","title":"Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition","description":"Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.280"},{"groupId":"OG001","value":"-1.04","spread":"0.278"},{"groupId":"OG002","value":"-1.18","spread":"0.270"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.039"},{"groupId":"OG001","value":"-3.52","spread":"1.035"},{"groupId":"OG002","value":"-6.79","spread":"1.056"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"3.4"},{"groupId":"OG001","value":"2.8","spread":"3.3"},{"groupId":"OG002","value":"8.4","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.2"},{"groupId":"OG001","value":"6.8","spread":"1.2"},{"groupId":"OG002","value":"6.2","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.3"},{"groupId":"OG001","value":"0.7","spread":"0.3"},{"groupId":"OG002","value":"0.2","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.3"},{"groupId":"OG001","value":"-0.7","spread":"0.3"},{"groupId":"OG002","value":"-0.8","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.3"},{"groupId":"OG001","value":"-0.7","spread":"0.3"},{"groupId":"OG002","value":"-0.6","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.2"},{"groupId":"OG001","value":"-0.9","spread":"0.2"},{"groupId":"OG002","value":"-1.0","spread":"0.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":237},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Diarrhoea"]}}}